Correlation Between Body Composition and Pathologic Grade/Prognosis in GEP-NENs: A Retrospective Study
Completed
- Conditions
- Neuroendocrine Tumors
- First Posted Date
- 2025-05-21
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Tongji Hospital
- Target Recruit Count
- 633
- Registration Number
- NCT06983106
- Locations
- 🇨🇳
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
Wearable Devices Assist in the Detection, Screening, and Management of Major Diseases in Middle-aged and Elderly Populations
Not Applicable
Not yet recruiting
- Conditions
- Coronary StenosisParkinson DiseaseCerebral Arterial DiseasesThyroid DysfunctionHypertensionHeart FailurePeripheral Arterial Occlusive Disease
- First Posted Date
- 2025-05-20
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- Tongji Hospital
- Target Recruit Count
- 800
- Registration Number
- NCT06980064
Efficacy and Safety of Sanggua Tablets in the Treatment of Patients With Impaired Glucose Tolerance and Mild Type 2 Diabetes
Early Phase 1
Recruiting
- Conditions
- Diabetes Mellitus, Type 2Impaired Glucose Tolerance
- Interventions
- Drug: Sanggua tabletsDrug: Placebo
- First Posted Date
- 2025-05-09
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- Tongji Hospital
- Target Recruit Count
- 84
- Registration Number
- NCT06964620
- Locations
- 🇨🇳
Tongji Hospital, Wuhan, Hubei, China
Fluzoparib+Bevacizumab/Dietary Intervention vs Fluzoparib Monotherapy as First-line Maintenance in HRD+/- Advanced Ovarian Cancer
Phase 3
Not yet recruiting
- Conditions
- Ovarian Cancer
- Interventions
- First Posted Date
- 2025-05-01
- Last Posted Date
- 2025-05-01
- Lead Sponsor
- Tongji Hospital
- Target Recruit Count
- 424
- Registration Number
- NCT06954584
- Locations
- 🇨🇳
Tongji Hospital, Wuhan, Hubei, China
Iparomlimab and Tuvonralimab as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With High Risk of Recurrence
Phase 2
Not yet recruiting
- Conditions
- Resectable Hepatocellular Carcinoma With High Risk of Recurrence
- Interventions
- Drug: Iparomlimab and Tuvonralimab (QL1706)Procedure: Partial hepatectomyProcedure: TACE
- First Posted Date
- 2025-05-01
- Last Posted Date
- 2025-05-01
- Lead Sponsor
- Tongji Hospital
- Target Recruit Count
- 27
- Registration Number
- NCT06954116
- Locations
- 🇨🇳
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
Exploratory Clinical Study on the Safety and Efficacy of CAR-T Cell Therapy in the Treatment of Relapsed/Refractory Myeloid Malignancies
Phase 1
Not yet recruiting
- Conditions
- Myeloid MalignanciesCAR-T
- Interventions
- Drug: CD33/CD123/CLL-1 CAR-T Cells
- First Posted Date
- 2025-04-08
- Last Posted Date
- 2025-04-08
- Lead Sponsor
- Tongji Hospital
- Target Recruit Count
- 45
- Registration Number
- NCT06917105
- Locations
- 🇨🇳
Tongji Hospital affiliated to Tongji Medical College of Huazhong University, WuHan, Hubei, China
A Clinical Study of Glycerol Phenylbutyrate in Chinese Patients With Urea Cycle Disorders
Not yet recruiting
- Conditions
- Urea Cycle Disorders
- Interventions
- First Posted Date
- 2025-04-01
- Last Posted Date
- 2025-04-01
- Lead Sponsor
- Tongji Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT06904027
- Locations
- 🇨🇳
Peking University First Hospital, Beijing, Beijing, China
🇨🇳Guangzhou Women and Children's Medical Center, Guangzhou, Guangdong, China
🇨🇳Tongji Hosipital, Wuhan, Hubei, China
Equecabtagene Autoleucel Injection (Eque-cel) for Relapsed/Refractory Systemic Lupus Erythematosus (SLE)
Not Applicable
Recruiting
- Conditions
- Systemic Lupus Erythematosus (SLE)Lupus Nephritis (LN)
- Interventions
- First Posted Date
- 2025-03-30
- Last Posted Date
- 2025-03-30
- Lead Sponsor
- Tongji Hospital
- Target Recruit Count
- 6
- Registration Number
- NCT06902844
- Locations
- 🇨🇳
Tongji Hospital, Wuhan, Hubei, China
Monoclonal Antibody-Based Therapies for AQP4-Positive NMOSD
Not yet recruiting
- Conditions
- NMO Spectrum Disorder
- Interventions
- Drug: Mab Therapy
- First Posted Date
- 2025-03-25
- Last Posted Date
- 2025-03-26
- Lead Sponsor
- Tongji Hospital
- Target Recruit Count
- 200
- Registration Number
- NCT06885957
- Locations
- 🇨🇳
Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
Clinical Evaluation of New Biomarkers for Ischemic Cerebrovascular Disease
Not yet recruiting
- Conditions
- Ischemic StrokeIschemic Cerebrovascular Disease
- First Posted Date
- 2025-03-24
- Last Posted Date
- 2025-04-22
- Lead Sponsor
- Tongji Hospital
- Target Recruit Count
- 7000
- Registration Number
- NCT06890702
- Locations
- 🇨🇳
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology,, Wuhan, Hubei, China
© Copyright 2025. All Rights Reserved by MedPath